NEW YORK (AP) — Shares of Avanir Pharmaceuticals soared Monday after the company reported positive clinical trial results for a drug that is designed to treat agitation in Alzheimer's disease patients.
The company said patients who were treated with AVP-923 were less agitated than patients given a placebo. The mid-stage clinical study lasted 10 weeks and included 220 patients, and the patients were evaluated with a questionnaire used to measure disturbance in patients with dementia.
11:01 Why Yahoo CEO Marissa Mayer’s $141 Million Payday Is Safe From the Hack Cover-Up14
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High11
21:52 Netflix nears 94 million subscribers 10 years after streaming launch21
22:33 Allergan to pay $15 million over failing to disclose merger talks19